Abstract-A single-nucleotide polymorphism (SNP) is a single base change in the DNA sequence and is the most common polymorphism. Since some SNPs have a major influence on disease susceptibility, detecting SNPs plays an important role in biomedical research. To take fully advantage of the nextgeneration sequencing (NGS) technology and detect SNP more effectively, we propose a Bayesian approach that computes a posterior probability of hidden nucleotide variations at each covered genomic position. The position with higher posterior probability of hidden nucleotide variation has a higher chance to be a SNP. We apply the proposed method to detect SNPs in two cell lines: the prostate cancer cell line PC3 and the embryonic stem cell line H1. A comparison between our results with dbSNP database shows a high ratio of overlap (>95%). The positions that are called only under our model but not in dbSNP may serve as candidates for new SNPs.
I. INTRODUCTION
A single-nucleotide polymorphism is a DNA sequence variation when one single nucleotide (A, T, C or G) in the genome is altered, such as an A, is replaced by one of the other three nucleotides C, G, or T. Whether a SNP has functional impact on the individual largely depends on the genomic location (coding region, intron, etc) and whether it leads to amino acid change after translation. Those functional SNPs have great potential to be biomarkers and therapeutic targets and therefore are especially interesting. So far, great endeavors have been made to SNP discovery and recently developed Next-generation Sequencing (NGS) technique has largely facilitated this process.
NGS is an emerging high-throughput technology that produces genome-wide data enabling unprecedented access to comprehensive genetic information. Detection of genome-wide variation is one of the most important applications of NGS. For example, Genome-Wide Association Studies (GWAS) examines the relationships between millions of SNPs and traits. The 1000 Genome Project utilizes NGS technology and aims to produce an extensive public catalog of human genetic variation [1] .
Two different types of approaches have been taken to detect SNPs. The first type relies upon amplification of DNA using the polymerase chain reaction (PCR) to reduce the complexity of the genome and works on re-sequencing data from diploid samples. These algorithms examine chromatogram trace files and detect variants by extracting or comparing signals in the peaks of traces. The widely used software using these algorithms include PolyPhred [2] , SNPdetector [3] , and novoSNP [4] . The second type is based on detecting sequence differences among cloned DNA samples. Two representative software are MAQ [5] and Atlas-SNP2 [6] . MAQ proposes a Bayesian approach to call variants by considering correlation of sampling and error rates at one particular position. Atlas-SNP2 takes into account sequence context in training datasets to sift through large amounts of high-throughput re-sequencing data and pick out genetic variants from ubiquitous sequencing errors. However, most of above software were not designed to handle NGS data. An effective and efficient algorithm for SNP discovery in NGS data will provide valuable information for downstream analysis.
In this study, we propose a Bayesian approach to estimate the probability of mismatch due to SNPs by computing posterior probability of hidden nucleotide variations at each covered genomic position from NGS data. Note that, during read alignment the base-level sequence mismatches can result from either sequencing errors [7] or hidden nucleotide variations such as SNPs and our approach will especially take these into consideration. The main idea is to model the base-level sequencing error rates using observed mismatch profiles. We 2012 IEEE International Workshop on Genomic Signal Processing and Statistics (GENSIPS) December 2-4, 2012, Washington, DC, USA 978-1-4673-5236-9/12/$31.00 ©2012 IEEE apply our method to data sets on PC3 and H1 cell lines.
The paper proceeds as follows. We introduce the proposed probability model along with MCMC techniques in Section II. Section III shows the effectiveness of our model by applying to prostate cancer cell line PC3 data and comparing with MAQ. In Section IV, we apply our model to stem cell line H1 data. We conclude with a discussion in Section V.
II. METHODOLOGY

A. Probability model
We will apply the proposed model independently to each covered genomic position. This strategy allows us to analyze different positions in parallel, achieving fast computational speed. For a given nucleotide position t on the reference genome, suppose there are K t unique reads overlapping with it. Denote the set U t = {U kt } Kt k=1 the labels of all the unique reads that overlap with the position t. Note that here "overlap" means partial match. For example, if t = 101 and the length of short read is 35, any overlapping unique read will have a starting position in [67, 101] . For a unique read U kt ∈ U t , let {e kt = 1} and {e kt = 0} respectively denote mismatch or perfect match between the unique read U kt and position t on the reference genome. So the mismatch profile at nucleotide position t is e t = {e kt , k = 1, . . . , K t }.
To estimate the mismatch probability q kt between the base at position t on the reference genome and the corresponding base of a unique read U kt , we write q kt as a function of α kt , the sequencing error rate, and β kt , the probability of hidden nucleotide variations. Following the law of addition, denote A the event {there is a sequencing error} and B the event that {there is a hidden nucleotide variation}, then q = P r(A ∪ B) = P r(A) + P r(B) − P r(A)P r(B). Specifically, using our notation, let
In our subsequent data analysis, we fix the values of α kt and estimate β kt . Recall that for the k th unique read that overlaps with genomic position t, α kt is the sequencing error rate. During mapping, a mapping quality character was assigned to each base of the reads. Let Z c denote the count of bases to which a quality character c was assigned, and Z cm denote the count of aforementioned bases that have mismatches. If the corresponding base of a unique read U kt was assigned quality character c, then the corresponding quality score is defined as α kt = Z cm /Z c . Using the quality scores from millions of unique reads in the data, we can reliably estimate α kt based on the observed sequencing error rates, rather than imposing a prior distribution on the α kt . We write the likelihood contribution from the unique reads at position t, which is given by
In (2), the only unknown variable is β kt . Given a genomic position t, there are three possible hidden nucleotide variations between the reference genome and aligned unique reads. For example, if the base at position t on the reference genome is A, there are three possible base substitutions: A-T, A-C and A-G. We assume that the probability of the three possible hidden nucleotide variations types to be β t = {β it , i = 1, 2, 3} for notation simplicity, where β 1t , β 2t , β 3t > 0 and β 1t + β 2t + β 3t < 1. If read k exhibits a mismatch at position t, i.e. {e kt = 1}, then β kt ∈ β t .
Denoting Dir(a, b, c, d ) a Dirichlet distribution with density ∝ β a−1 Dir(a, b, c, d ).
In the subsequent analysis, we assume a = b = c = 0.001 and d = 1, since the SNP rate in human genome is about 0.1%.
B. Markov chain Monte Carlo simulations
We augment the parameter space [8] and employ a Gibbs sampler to simulate the unknown parameters β t . Let g t be the base at position t, and g kt the base at the corresponding position of k th unique read that overlapped with position t. Here, g t is known from the reference genome. For g kt 's, they take values in {A, C, G, T}. If read k exhibits a mismatch at position t, i.e. {e kt = 1}, then
where C 1 , C 2 , C 3 are the nucleotide types different from that at the position t on the reference genome.
Let S it = {k : g kt = C i } and N it = S it for i = 1, 2, 3, where · denotes the number of elements in one set.
The basic idea is to introduce a latent Bernoulli variable with a conditional distribution defined by
for k ∈ {S 1t , S 2t , S 3t }. With the augmented Bernoulli distribution, we can easily show that
The proposed Gibbs sampler is as follows:
it = , where is an arbitrary small probability close to zero for i = 1, 2, 3.
• Step 2: In the s-th iteration, sample u
• Step 3: Sample β t = (β 1t , β 2t , β 3t ) from (3).
• Step 4: Iterate steps 1 to 3 S times, for a large integer S. For the special case in which N it = 0, set u In our analysis, the number of iterations S was set to 1,000 with the first 200 iterations as burn-in. The Markov chain converged fast and mixed well.
III. PROSTATE CANCER CELL LINE PC3 DATA ANALYSIS
We apply our method to a prostate cancer cell line PC3 dataset, aiming to detect SNPs. Prostate cancer is the most common cause of death from cancer in men over age 75.
We use Bowtie [9] to map the sequencing data and calculate the coverage with BEDTools [10] . 61.8% of the genome is covered with average sequencing depth of 1.55. And 62.6% of the exon regions are covered with the average sequencing depth of 1.62.
Recall that β t denotes the probability of hidden nucleotide variations at genomic position t on the reference genome, so the position with higher posterior probability of β t will have a higher chance to be a SNP. We will call a position a potential SNP if there exists β > β 0 , where β ∈ β t and β 0 is a cutoff value. To determine the optimal cutoff, we compare the identified SNP candidates with dbSNP [11] using ANNOVAR [1] . When β 0 = 0.5, 685,277 candidate SNPs are identified and 634,477 (92.6%) of them are found in dbSNP. When β 0 = 0.75, 198,645 candidate SNPs are identified and 188,989 (95.1%) of them are found in dbSNP.
For comparison, we apply MAQ to the same data. MAQ targets 387,931 candidate SNPs, in which 233,283 (60%) are in dbSNP. The proportion of identified SNPs falling into dbSNP can be used as a measure of method reliability. Using above criteria, our method outperforms MAQ since our method not only identifies more SNPs, but also has higher quality.
For each potential SNP, we compute the proportions of one particular nucleotide variation and compare them with posterior probability of this hidden nucleotide variation. For example, if the nucleotide at genomic position t is A, and there are 100 short reads mapped to this position with 10 T's, 15 C's and 75 A's. We can get at this position, the proportion of A-T substitution is 0.1; the proportion of A-C substitution is 0.15. Fig. 1 shows the scatter plot with smoothed densities color representation of posterior probability of hidden nucleotide variations versus the proportions of nucleotide changes for the potential 28,057,824 SNPs. Most of the points are on the 45-degree line, which shows the posterior probability of hidden nucleotide variation has very high correlation with proportion rate. In addition, there exist many points, whose observed proportion is 1 and the corresponding posterior probability ranges from 0.5 to 1. This is due to Bayesian shrinkage since we borrow strength from the sequencing errors.
IV. STEM CELL LINE H1 DATA ANALYSIS
We apply our model to stem cell line H1 data that is almost 20 times larger than PC3 data and has relatively high and uniform sequencing depth. H1 cell line is one of the most extensively studied and characterized stem cell lines. Except for the bisulfite-seq and smRNA-seq, all the sequencing data of H1 cell line available at NCBI before November 2011 are used in our analysis. The complete list of data we used From these results, we believe that the candidate SNPs with β ≥ 0.75 are trustworthy, because the percentages of the candidate SNPs in dbSNP are higher than 0.95 for both PC3 and H1 data. To determine whether the cutoff is appropriate, we adopt the method introduced by Newton et al. [12] and Müller et al. [13] to control false discovery rate (FDR). For a given cutoff β 0 , we define FDR(
, where I (·) is the indicator function. Fig. 3 plots the estimated FDR versus selected positions whose β are larger than 0.75. We can see that the FDR is estimated to be less than 0.1.
Because of the large data size of PC3 data (14 GB) and H1 data (200 GB) after mapping, computation is challenging here. We employ an efficient way to implement the algorithm in C++. The program outputs posterior probability for each position with mismatch(es). The PC3 data analysis is carried out on iMac, which equips with 2.8 GHz Intel Core i7 CPU and 16GB memory. The calculation is done within 3 hours. openMP option is enabled to facilitate the parallel computing by chromosome. The H1 data analysis is carried out on MDACC high performance computing (HPC) cluster, which equips with AMD Opteron(tm) Processor 6128 HE, and 32 GB RAM per node. The calculation is performed for each chromosome in parallel and all the calculations finishes within 20 hours. The code is available upon requested.
V. CONCLUSION
We propose a Bayesian method to detect SNPs in this paper and apply our method to two data sets: prostate cancer cell line PC3 and stem cell line H1. While the sequencing depth of PC3 is low and uneven and H1 has relatively high and uniform sequencing depth, our method works well for both. Our result will provide a useful reference to common cell lines. The data was originally obtained for epigenetic studies of histone modifications using ChIP-Seq technique. We show that the data originally intended for ChIP-Seq studies can be mined for SNP information. Since there are thousands of ChIP-Seq experiments conducted each year, we expect our method to have a wide range of applications.
The proposed Bayesian SNP calling method utilizes quality score of the sequence reads and mismatch profiles between the unique reads and the reference genome in determining the variants. The method is fast, capable of processing whole genome data at 20-fold average coverage in reasonable amount of time. We show that our method is substantially better than MAQ in that it finds more SNPs with higher quality.
